HIV/AIDS Clinical Trials in Los Angeles

Showing 641-648 of 648 trials

A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients

NCT00002322

To determine the tolerance and antiviral response of two different doses of atevirdine mesylate (U-87201E) in symptomatic HIV-positive patients with CD4 counts of 50-350 cells/mm3, who also take zidovudine (AZT).

HIV Infections

Pharmacia and Upjohn

Los Angeles, California, United States • Orange, California, United States • San Francisco, California, United States +9 more locations

COMPLETEDPhase 1< 1 mile

A Study of Letrazuril in the Treatment of AIDS-Related Diarrhea

NCT00001018

To determine the pharmacokinetic profile of single doses of letrazuril in patients with AIDS-related cryptosporidial diarrhea; to determine the dose proportionality of single escalating doses of letrazuril; to determine steady-state concentrations of letrazuril; to evaluate the safety and efficacy of escalating doses of letrazuril, compared with placebo, for patients with AIDS-related cryptosporidial diarrhea. Letrazuril, the p-fluor analog of diclazuril, has been shown in an animal model to prevent infections by organisms closely related to the intracellular parasite Cryptosporidium. Reliable data are needed to show the effectiveness of letrazuril in treating AIDS-related cryptosporidial diarrhea.

CryptosporidiosisHIV Infections

National Institute of Allergy and Infectious Diseases (NIAID)32 participants

Los Angeles, California, United States • New York, New York, United States • New York, New York, United States +1 more locations

A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients

A Study of Letrazuril in the Treatment of AIDS-Related Diarrhea

HIV/AIDS Trials in Other Cities

SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy

Comparing Side Effects of Two Forms of Videx in HIV-Infected Adults

A Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients

A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine

A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDS

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

Other Conditions in Los Angeles